Use of exhaled nitric oxide measurements to guide treatment in chronic asthma.
By Andrew D. Smith, J. Cowan, Karen Brassett, G. Herbison, D. Taylor. New England Journal of Medicine, 2005
1,016 citations recorded by the source corpus.
Subfields: Physiology, Pulmonary and Respiratory Medicine, Sociology and Political Science
View Paper: https://www.semanticscholar.org/paper/f5af6e11fa96fb1ecaff54c9b460bad9510009e8
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Physiology
Citations in the corpus
- Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report (2007, background): “In one high-quality study in adults, changes in therapy aimed at controlling eNO levels led to the use of a lower ICS dose to maintain the same degree of asthma control (285).”
- An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. (2009, result): “All three studies reported fewer exacerbations when treatment was guided by FENO, but the results were not statistically significant (262, 325, 326).”
- Cluster Analysis and Clinical Asthma Phenotypes (2008, result): “In keeping with this, a recent study using exhaled nitric oxide (FENO) as a measure of eosinophilic airway inflammation in asthma showed that FENO-guided management resulted in lower inhaled corticosteroid use without compromising asthma control ( 21 ).”
- Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. (2010, neutral): “FENO has been used clinically as a noninvasive biomarker to diagnose asthma and evaluate therapeutic responsiveness (31), but more recent studies suggest limitations of its predictive value (32).”
- Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma (2007, neutral): “Several studies indicate that monitoring biomarkers—such as measures of hyperresponsiveness, sputum eosinophils, and FeNO—can be used to guide treatment decisions (Green et al. 2002; Smith et al. 2005; Sont et al. 1999).”
- International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma (2013, neutral): “Page 47 of 112 adults [256, 261, 262].”